This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Molnupiravir oral

Updated 2 Feb 2023 | Other antivirals


Oral formulation of molnupiravir.

Drugs List

  • LAGEVRIO 200mg capsules
  • molnupiravir 200mg capsules
  • Therapeutic Indications


    Coronavirus disease 2019 (COVID-19) - treatment

    Treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.


    Molnupiravir should be administered as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of the onset of symptoms.


    800mg (four 200mg capsules) every 12 hours for 5 days.

    The safety and efficacy of molnupiravir when administered for periods longer than 5 days have not been established.

    Additional Dosage Information

    Missed dose
    If a patient misses a dose within 10 hours of the time molnupiravir is usually taken, then the patient should take as soon as possible and resume the normal dosing schedule. If a patient misses a dose by more than 10 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double dose.


    Children under 18 years

    Precautions and Warnings

    Females of childbearing potential

    Female: Contraception required during and for 4 days after treatment
    Breastfeeding: Do not breastfeed during and for 4 days after treatment

    Pregnancy and Lactation


    Molnupiravir is contraindicated during pregnancy.

    The manufacturer does not recommend taking molnupiravir during pregnancy. At the time of writing there is no data regarding the use of molnupiravir during pregnancy. Animal studies have shown reproductive toxicity.


    Molnupiravir is contraindicated during breastfeeding.

    The manufacturer does not recommend taking molnupiravir during breastfeeding and for four days after the last dose. It is unknown whether molnupiravir or any of its components are present in human breast milk, affect human milk production, or have effect on the breastfed infant. Animal studies have not been conducted.

    Side Effects



    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: November 2021

    Reference Sources

    Summary of Product Characteristics: Lagevrio 200mg hard capsules. Merck Sharp & Dohme (UK) Limited. Revised November 2021.

    NICE Evidence Services Available at: Last accessed: 28 January 2022

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.